Founded in 1986, Shire PLC was a British biotechnology group dedicated to addressing rare diseases and specialized medical conditions. The company focused on developing products in various therapeutic areas, including hematology, immunology, neuroscience, ophthalmics, lysosomal storage disorders, gastrointestinal, internal medicine, endocrine disorders, hereditary angioedema, and oncology. Shire aimed to improve the quality of life for patients with rare and complex conditions through innovative treatments.
Notable figures associated with Shire included CEO Flemming Ornskov and CFO Thomas Dittrich. The company achieved significant financial success, with a revenue of $15.16 billion and a net income of $4.27 billion in 2017. Shire's impactful contributions to biotechnology and pharmaceuticals culminated in its acquisition by Takeda Pharmaceutical Company in 2019, marking the end of its independent operations but ensuring the continuation of its mission under a larger umbrella.
Companies similar to Shire include Alexion Pharmaceuticals, BioCryst Pharmaceuticals, Astria Therapeutics and Harmony Biosciences.
Shire was founded in 1986.
Shire's headquarters is located in Lexington, MA, US.
Shire's most recent funding round was for $62.4B (USD) in January 2019.
As of Jan 8, 2019, Shire has disclosed funding of $62.4B (USD). Undisclosed round amounts are excluded.
Alexion Pharmaceuticals
alexion.com

BioCryst Pharmaceuticals
biocryst.com

Astria Therapeutics
astriatx.com

Harmony Biosciences

Ultragenyx Pharmaceutical
ultragenyx.com

Amicus Therapeutics
amicusrx.com

Gilead Sciences
gilead.com

Royalty Pharma
royaltypharma.com

Rigel Pharmaceuticals
rigel.com

PTC Therapeutics
ptcbio.com

AstraZeneca
astrazeneca.com

Biogen
biogen.com
Citrine Medicine

Empire Biotechnologies

Sanofi
sanofi.com